All In Biotech

Drug Trial Radar · NCT06864130

A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures

The Alendronate Discontinuation Study

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,400

Planned (sponsor's estimate)

Start

Feb 21, 2025

Primary completion

Mar 1, 2029

Study completion Sep 15, 2029

Sponsor

Lead sponsor
Odense University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to study the effects of discontinuation of Alendronate treatment for three years. The participants are postmenopausal women with osteoporosis, who have had a treatment period without fractures. The study will answer: * What is the rate of fragility fractures during the study? The hypothesis is that discontinuation of Alendronate after a fracture-free period does not raise the 3-year fracture risk. * Are there predictors of significant bone loss after discontinuation of Alendronate? The hypothesis is that clinical, biochemical, cellular, or molecular characteristics can predict bone loss. Researchers will compare the outcomes of discontinuation of Alendronate with continuing treatment. Participants will be randomly assigned to a group. Participants will: * Either take alendronate once weekly for three years OR discontinue their treatment * Visit the clinic at 6 and 18 months for blood samples * Visit the clinic at the start of the study and after 1, 2, and 3 years for bone scans and blood samples.

Conditions

  • Osteoporosis in Post-menopausal Women

Interventions

  • Alendronate 70mg weeklyDrug

    The intervention is discontinuation of Alendronate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fragility fracturesTime frame: From enrollment to the end of the 3 year study period.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Aalborg University Hospital

    Aalborg, Denmark · Not yet recruiting

  • Bispebjerg Hospital

    Copenhagen, Denmark · Not yet recruiting

  • Esbjerg Og Grindsted Sygehus

    Esbjerg, Denmark · Recruiting

  • Copenhagen University Hospital (Herlev)

    Herlev, Denmark · Recruiting

  • Nordsjaellands Hospital (Hillerød)

    Hillerød, Denmark · Recruiting

  • Hvidovre Hospital

    Hvidovre, Denmark · Not yet recruiting

  • Odense University Hospital

    Odense, Denmark · Recruiting

  • Sygehus Sønderjylland, Tønder

    Tønder, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.